Biosino Bio-Technology and Science Incorporation provided unaudited consolidated earnings guidance for the year ended 31 December 2023. for the year, Group is expected to record a net loss within a range of RMB 18,000,000 to RMB 22,000,000 for the Reporting Period as compared to a net profit of approximately RMB 14,202,000 for the year ended 31 December 2022. The Board considers that the expected loss for the Reporting Period is mainly attributable to (i) a decrease in the Group's gross profit due to (a) a drop in market demand as affected by changes in public health prevention and control policies both domestically and abroad; and (b) a drop in price of products as affected by industry centralised procurement; and (ii) an increase in the Group's research and development expenses on the its advantageous products, such as flow cytometry and supporting reagents.
Biosino Bio-Technology and Science Incorporation
Equities
8247
CNE100000288
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.94 HKD | 0.00% | +34.29% | +17.50% |
1st Jan change | Capi. | |
---|---|---|
+17.50% | 17.38M | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.29B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- 8247 Stock
- News Biosino Bio-Technology and Science Incorporation
- Biosino Bio-Technology and Science Incorporation Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023